JPMorgan placed Inspire Medical (INSP) on “Positive Catalyst Watch” ahead of the SURMOUNT-OSA readout this spring. While GLP-1 noise has largely subsided across medical technology, the pending readout of SURMOUNT-OSA this spring has kept an overhang on Inspire shares, creating a “unique buying opportunity,” the analyst tells investors in a research note. The firm does not anticipate GLP-1s having a meaningful impact on Inspire adoption and thinks more patients are likely to fall into rather than out of the company’s funnel. JPMorgan fully expects SURMOUNT-OSA to show a statistically significant reduction in Apnea-Hypopnea Index and body mass index compared to placebo and be a positive trial for Eli Lilly (LLY), but does not see the primary endpoint and likely outcomes matching the efficacy of CPAP or Inspire.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- IBM upgraded, Hertz downgraded: Wall Street’s top analyst calls
- Inspire Medical initiated with a Buy at Jefferies
- Inspire Medical price target raised to $240 from $210 at Lake Street
- Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2023 Financial Results on February 6, 2024
- Inspire Medical management to meet with Piper Sandler